GlassScriptPhysician profile
Laura Hostovich
NPI 1588667943
$8,167.82
in general payments reported to CMS, 2019-2025
60 companies · $2,510 in 2025
The $2,510 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $402 · 2022: $1,371 · 2023: $1,517 · 2024: $2,368 · 2025: $2,510.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,394.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,394.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $923.10 | 2021-2025 | |
| Janssen Biotech, INC. | $660.35 | 2022-2025 | Rybrevant, Erleada, Carvykti |
| Incyte Corporation | $527.27 | 2021-2025 | Jakafi, Monjuvi, Zynyz |
| Glaxosmithkline, LLC. | $383.46 | 2022-2025 | Zejula, Jemperli, Ojjaara |
| Bayer Healthcare Pharmaceuticals INC. | $357.19 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $330.72 | 2021-2025 | Lynparza, Calquence, Enhertu |
| Daiichi Sankyo INC. | $326.04 | 2022-2025 | Enhertu, Injectafer, Datroway |
| E.R. Squibb & Sons, L.L.C. | $322.71 | 2022-2025 | Reblozyl, Opdivo, Camzyos |
| Takeda Pharmaceuticals U.S.A., INC. | $315.61 | 2021-2025 | Vpriv, Iclusig, Alunbrig |
| Abbvie INC. | $292.37 | 2022-2025 | |
| Pharmaessentia USA Corporation | $262.47 | 2023-2025 | Besremi |
| Sobi, INC | $219.29 | 2022-2025 | |
| Pfizer INC. | $212.29 | 2023-2025 | |
| Seagen INC. | $204.09 | 2021-2023 | Tivdak, Adcetris, Padcev |
| Regeneron Healthcare Solutions, INC. | $183.52 | 2022-2025 | Libtayo, Lynozyfic |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $179.39 | 2022-2025 | Polivy, Tecentriq, Venclexta |
| Merck Sharp & Dohme LLC | $171.27 | 2022-2025 | Keytruda, Welireg, Lynparza |
| Genzyme Corporation | $169.37 | 2021-2025 | |
| Aveo Pharmaceuticals, INC. | $160.58 | 2022-2025 | Fotivda |
| Spectrum Pharmaceuticals INC. | $119.70 | 2023-2025 | Rolvedon |
| Eisai INC. | $107.84 | 2022-2025 | |
| Exelixis INC. | $107.60 | 2024-2025 | Cabometyx |
| Novocure INC. | $104.65 | 2024 | Optune Lua (Novottf-200t) |
| Lilly USA, LLC | $87.97 | 2022-2025 | Jaypirca, Verzenio, Retevmo |
| Amgen INC. | $87.94 | 2022-2023 | Lumakras, Xgeva, Nplate |
| Janssen Pharmaceuticals, INC | $87.23 | 2021-2024 | Xarelto |
| Sumitomo Pharma America, INC. | $84.94 | 2023-2025 | Orgovyx |
| Astellas Pharma US INC | $80.23 | 2022-2024 | Padcev, Xtandi |
| Azurity Pharmaceuticals, INC. | $73.85 | 2024-2025 | Danziten, Vivimusta |
| Adc Therapeutics America, INC. | $67.61 | 2025 | |
| Taiho Oncology, INC. | $60.86 | 2022-2023 | |
| Rigel Pharmaceuticals, INC. | $58.25 | 2022-2025 | Tavalisse, Rezlidhia, Gavreto |
| Gilead Sciences, INC. | $55.58 | 2021-2025 | Trodelvy |
| Kite Pharma, INC. | $52.91 | 2025 | Yescarta |
| Emd Serono, INC. | $47.64 | 2025 | |
| Dendreon Pharmaceuticals LLC | $45.72 | 2023-2025 | Provenge |
| Mirati Therapeutics, INC. | $42.94 | 2023-2024 | Krazati |
| Ipsen Biopharmaceuticals, INC | $42.84 | 2022-2024 | Onivyde |
| Blueprint Medicines Corporation | $40.39 | 2022-2023 | Ayvakit |
| Iovance Biotherapeutics, INC. | $39.84 | 2025 | Amtagvi |
| Puma Biotechnology, INC. | $38.26 | 2024 | |
| Alnylam Pharmaceuticals INC. | $32.56 | 2024 | Givlaari |
| Celgene Corporation | $32.29 | 2025 | Opdivo |
| Pharmacosmos Therapeutics INC. | $29.27 | 2025 | Monoferric |
| Pharmacyclics LLC, An Abbvie Company | $28.80 | 2022 | |
| Beigene USA, INC. | $28.11 | 2023 | Brukinsa |
| Array Biopharma INC | $27.63 | 2025 | Lorbrena |
| Global Blood Therapeutics, INC. | $24.92 | 2022 | |
| Beone Medicines USA, INC. | $24.77 | 2025 | Tevimbra |
| Tersera Therapeutics LLC | $23.80 | 2022 | |
| Accord Healthcare, INC. | $23.59 | 2025 | |
| Sun Pharmaceutical Industries INC. | $21.52 | 2025 | |
| G1 Therapeutics, INC. | $21.34 | 2023 | Cosela |
| Recordati_rare_diseases_inc. | $18.85 | 2023 | Sylvant |
| Alexion Pharmaceuticals, INC. | $18.65 | 2022 | |
| Kyowa Kirin, INC. | $18.31 | 2021 | |
| Morphosys, US INC. | $16.47 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.80 | 2021 | |
| Acrotech Biopharma INC. | $13.93 | 2024 | Beleodaq |
| Dova Pharmaceuticals | $12.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Hostovich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.